{"product_id":"podd-bcg-matrix","title":"(PODD) Insulet Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Insulet Corporation BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnipod 5 U.S. AID\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmnipod 5 U.S. AID stayed Insulet Corporation’s main growth engine at end-2025, with full-year 2025 revenue of about $2.1 billion, up roughly 18% year over year. The tubeless, wearable pump targets the largest insulin-pump market in the portfolio and kept gaining share in a fast-growing automated insulin delivery category. That makes it a clear Star in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnipod 5 Type 2 Diabetes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmnipod 5’s adult type 2 diabetes clearance in 2024, plus its 2024 U.S. rollout, opened a far larger insulin-treated pool than Insulet Corporation’s type 1 base. That makes it a clear BCG \"Star\": high growth potential, but still early in adoption, so sales and education spend stay high. Insulet Corporation’s 2024 net sales were about $2.0 billion, showing the product platform is already scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnipod 5 International Rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsulet is still rolling out Omnipod 5 beyond the U.S., with launches and expansion in Europe, Canada, and Australia. That matters because non-U.S. adoption is still early, so the tubeless CGM-linked platform can keep taking share as payer access widens and more users switch from pumps with tubes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOmnipod 5 Pediatric 2+\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmnipod 5 Pediatric 2+ is a Star for Insulet Corporation because U.S. approval down to age 2 expands the addressable pediatric pool and lengthens customer lifetime value. In a global automated insulin delivery market that industry trackers project in the multi-billion-dollar range by 2030, early family adoption can lock in long use and stronger brand loyalty.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved for children age 2+\u003c\/li\u003e\n\u003cli\u003eBroadens long-term user pool\u003c\/li\u003e\n\u003cli\u003eSupports higher lifetime value\u003c\/li\u003e\n\u003cli\u003eBuilds brand in AID growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOmnipod 5 Dexcom G7\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmnipod 5 Dexcom G7 got a clear lift in 2025 as Dexcom G7 compatibility widened its appeal for users who want automated insulin delivery with a smaller, 10-day sensor. Better CGM pairing can speed moves away from older pump and sensor setups, which supports faster new-user conversion. That keeps Omnipod 5 in Insulet Corporation's premium growth slot.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDexcom G7 fit improved in 2025.\u003c\/li\u003e\n\u003cli\u003e10-day sensor lowers switching friction.\u003c\/li\u003e\n\u003cli\u003eSupports premium growth positioning.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnipod 5 Powers Insulet’s Fast-Growing AID Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsulet Corporation's Star is Omnipod 5: FY2025 net sales were about $2.1 billion, up 18% year over year, and U.S. adult type 2 clearance plus pediatric age 2+ support a larger, still-fast-growing AID market. Dexcom G7 compatibility and non-U.S. rollouts keep adoption high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eOmnipod 5\u003c\/td\u003e\n\u003ctd\u003e$2.1B sales\u003c\/td\u003e\n\u003ctd\u003eHigh growth, wider reach\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eInsulet BCG Matrix: spot Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG view of Insulet’s portfolio, quickly revealing growth bets, cash cows, and underperformers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Insulet assumptions, helping investors and teams verify key claims quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnipod DASH Installed Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAt end-2025, Omnipod DASH remained a mature, high-share platform inside Insulet's installed base, while Omnipod 5 grew faster. The DASH base still drives recurring pod and supply revenue, so it keeps cash flowing even as new-account growth slows. That is classic cash cow behavior: high share, low growth, steady monetization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePod Consumables Reorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePod consumables are Insulet Corporation’s clearest cash cow: each Omnipod pod lasts up to 3 days, so one user can need about 10 pods a month, creating repeat orders from the installed base. This recurring mix is stronger than one-time device sales and supports higher gross margin because the pod is a disposable consumable. In 2025, this engine kept driving most of Insulet Corporation’s revenue growth through repeat usage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Channel Refills\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmacy Channel Refills are a Cash Cow for Insulet Corporation because once patients start Omnipod therapy, refills repeat with low friction and stable demand. Insulet reported 2024 revenue of about $2.1 billion, and recurring pharmacy orders help turn that base into reliable cash flow with lower selling costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy Omnipod Users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy Omnipod users remain a Cash Cow for Insulet Corporation because older-system customers still need pods, controllers, and accessories, creating steady replacement revenue. In fiscal 2025, Insulet said total net sales rose to about $2.1 billion, but growth was led by Omnipod 5, so the older base is clearly a mature, slower-growing pool. These users still help fund AID expansion and international growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady replacement demand from installed base\u003c\/li\u003e\n\u003cli\u003eMature, low-growth pool versus Omnipod 5\u003c\/li\u003e\n\u003cli\u003eSupports funding for new-platform expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. Commercial Renewal Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsulet Corporation’s U.S. commercial renewal base is a Cash Cow because large payer and employer contracts keep Omnipod access steady and recurring. This base is less about new-user spikes and more about retention, so it supports predictable volume and cash flow. In FY2025, that stability mattered as U.S. commercial coverage stayed the core engine behind repeat orders and durable revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable payer and employer access\u003c\/li\u003e\n\u003cli\u003eRetention drives value, not rapid growth\u003c\/li\u003e\n\u003cli\u003eSupports recurring U.S. order volume\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulet’s Cash Cows: Recurring Pod Refills Power Steady Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsulet Corporation’s Cash Cows are its mature pod-consumable streams, led by Omnipod DASH and legacy user refills. These users keep ordering pods every 3 days, so revenue stays recurring even as Omnipod 5 takes the growth lead. FY2025 net sales were about $2.1 billion, and the installed base still funds cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow driver\u003c\/th\u003e\n\u003cth\u003eFY2025 fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePod refills\u003c\/td\u003e\n\u003ctd\u003eAbout 10 pods per user each month\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal net sales\u003c\/td\u003e\n\u003ctd\u003eAbout $2.1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eInsulet Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Insulet Corporation BCG Matrix you’re previewing is the exact same file you’ll receive after purchase. No placeholders or demo pages—just the full, professionally formatted report ready for immediate use.\u003c\/p\u003e\n\u003cp\u003eOnce purchased, this same document will be delivered to you for downloading, editing, or presenting. What you see here is what you get: a complete, analysis-ready BCG Matrix for Insulet Corporation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnipod Eros Legacy Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmnipod Eros is Insulet Corporation’s oldest legacy platform, so it fits the Dogs bucket. The installed base is shrinking, and growth looks minimal by end-2025. It still needs service, parts, and support, but it is not a future growth driver. That makes it a cash drain more than a growth asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePDM-Era Accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePDM-era accessories have little strategic upside for Insulet Corporation: they serve an older controller workflow, while Omnipod 5 is the growth engine. In FY2024, Insulet reported $2.08 billion in net sales, and legacy accessory demand kept shrinking as users moved to the newer system. Replacement volume is now low and mostly runoff, so this is a Dogs asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Legacy Hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsulet Corporation's discontinued legacy Omnipod hardware has weak BCG footing: it is a small carryover line, not a growth driver, and it is not broken out as a material revenue stream in current reporting. The core Omnipod platform is where Insulet is putting capital and demand, so older units likely have low share and little strategic pull. That makes them clear candidates for minimization, not reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall-Scale Obsolete Replacements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsulet Corporation's small-scale obsolete replacements fit Dogs: they serve only residual users, so demand is thin and the market is not growing. In 2025, Insulet still derived most value from Omnipod system sales, not old-system parts, so capital tied here earns little strategic return.\u003c\/p\u003e\n\u003cp\u003eThat makes this line low priority versus growth areas like new device launches and patient expansion. If a segment cannot scale beyond a narrow installed base, even steady revenue does not justify fresh investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eServes only residual users\u003c\/li\u003e\n\u003cli\u003eLow growth, low return\u003c\/li\u003e\n\u003cli\u003eCapital is better used elsewhere\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-Traction Legacy Accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-Traction Legacy Accounts at Insulet Corporation are small, old-system customers that are unlikely to turn into big growth drivers. They sit far below the Omnipod 5 base in economics, so they fit the \"Dog\" bucket: low share, low traction, and limited upside. These accounts are maintenance items, not expansion assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKeep servicing lean.\u003c\/li\u003e\n\u003cli\u003eDo not overinvest here.\u003c\/li\u003e\n\u003cli\u003ePrioritize Omnipod 5 growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulet’s Legacy “Dogs” Are Runoff, Not Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Insulet Corporation are the legacy Omnipod Eros and old PDM accessories: low growth, shrinking use, and little strategic pull versus Omnipod 5. Insulet posted $2.08 billion net sales in FY2024, but these older items are runoff, not growth. They should stay leanly serviced, not funded.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog item\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOmnipod Eros\u003c\/td\u003e\n\u003ctd\u003eLegacy runoff\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDM accessories\u003c\/td\u003e\n\u003ctd\u003eThin demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 net sales\u003c\/td\u003e\n\u003ctd\u003e$2.08 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnipod GO\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmnipod GO targets adults with type 2 diabetes on basal insulin, a large U.S. pool tied to the 38.4 million Americans with diabetes. The niche is still early, so adoption was uncertain at end-2025. It has growth upside, but it needs scale and repeat use to prove it can move from Question Mark to Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare is a real gap for Insulet Corporation: U.S. Medicare covered about 67 million people in 2025, but broader reimbursement still limits Omnipod adoption. If Insulet wins more government-covered users, share can rise fast; the payoff is large, but it is still unproven. Until reimbursement widens, this stays a Question Mark in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew-Country Launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsulet’s 2025 growth still leans on new-country launches: in Q1 2025, total revenue was $543.9 million and international revenue rose 31% year over year. That shows strong demand, but market share outside the U.S. is still early in many geographies. These launches need upfront spend on approvals, payor access, and local teams before they can mature.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLibre Sensor Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLibre integration could widen Insulet Corporation’s funnel if Abbott users convert, but it is still a share test, not a sure win. Insulet reported 2024 revenue of $2.03B, up 17.2%, so even a small lift in sensor-linked adoption can matter. If uptake stays weak, this remains a question mark with limited upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore Libre users can expand reach\u003c\/li\u003e\n\u003cli\u003eWeak uptake keeps growth capped\u003c\/li\u003e\n\u003cli\u003eConversion, not tech, drives payoff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMDI-to-Pump Switching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMDI-to-pump switching is still a big Question Mark for Insulet Corporation: the global diabetes pool reached about 589 million adults in 2025, but converting MDI users to Omnipod is not automatic. That makes this a high-growth, still-developing share opportunity, with adoption tied to ease of use, payer access, and clinician push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHuge addressable MDI user base\u003c\/li\u003e\n\u003cli\u003eConversion is still the key risk\u003c\/li\u003e\n\u003cli\u003eOmnipod can win share, if adoption improves\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulet’s Early-Stage Growth Bets Could Unlock Big Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsulet Corporation’s Question Marks are still early, but the upside is real: Omnipod GO targets part of the 38.4 million U.S. diabetes population, while Medicare’s 67 million covered lives in 2025 still limit access. International revenue rose 31% in Q1 2025 to $543.9 million, but share is not yet mature. Libre integration and MDI switching can lift growth if conversion improves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eQuestion Mark\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOmnipod GO\u003c\/td\u003e\n\u003ctd\u003e38.4M U.S. diabetes cases\u003c\/td\u003e\n\u003ctd\u003eBig pool, early adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare access\u003c\/td\u003e\n\u003ctd\u003e67M covered lives\u003c\/td\u003e\n\u003ctd\u003eReimbursement still a gap\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl. launches\u003c\/td\u003e\n\u003ctd\u003e$543.9M Q1 2025 revenue\u003c\/td\u003e\n\u003ctd\u003eGrowth needs scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191847690505,"sku":"podd-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/podd-bcg-matrix.webp?v=1783678593","url":"https:\/\/dcfanalyst.com\/products\/podd-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}